08:35 AM EST, 11/28/2025 (MT Newswires) -- Profound Medical ( PROF ) said Friday it is launching its Tulsa-AI Volume Reduction module to treat patients with benign prostatic hyperplasia (BPH), or enlarged prostate, at the Radiological Society of North America meeting in Chicago next week.

BPH, a non-cancerous enlargement of the prostate gland due to an overgrowth of prostate cells, is a common condition as men age.

The Tulsa Procedure is an incision-free procedure for prostate cancer, BPH, and patients who have both prostate cancer and BPH. With the TULSA-AI Volume Reduction module, physicians can "stack" multiple prostate cases in one day, using the same device hardware, clinical support staff and reimbursement codes, the company said.

"The use of AI to streamline the workflow and reduce procedure times is a significant advance that makes using TULSA-PRO for treating enlarged prostate just as efficient as other modern procedures, but with the advanced benefits of precision and customization to any prostate shape or size. We expect the reduced procedure times will increase adoption of the TULSA Procedure and triple Profound's total available market in prostate disease to about 600,000 patients annually," said chief executive Arun Menawat.